Evolus, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
—
13F top-10 QoQ
Top fund weight
Last report2 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Evolus, Inc.
7.11
−0.36 · −4.83%
Expected move
Inputsspot 7.47exp Jan 15ATM strike 7.5ATM straddle 1.78IV 68%
No other changes.
No other changes.
| Manager | Value | % base | |
|---|---|---|---|
| Nantahala | $38.9M | 11.36% | −12.15% |
| BlackRockindex-like | $33.6M | 9.81% | +12.83% |
| Braidwell | $21.9M | 6.40% | +1.61% |
| Frazier Life Sciences | $18.3M | 5.33% | 0.00% |
| Perceptive | $17.1M | 4.98% | +91.11% |
| Manager | Value | % base | |
|---|---|---|---|
| Nantahala | $38.9M | 11.36% | −12.15% |
| BlackRockindex-like | $33.6M | 9.81% | +12.83% |
| Braidwell | $21.9M | 6.40% | +1.61% |
| Frazier Life Sciences | $18.3M | 5.33% | 0.00% |
| Perceptive | $17.1M | 4.98% | +91.11% |
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Evolus, Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Evolus, Inc.'s 6 closest co-movers, none share that code.
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 3 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
—
—